激素疗法与化疗联合激素辅助疗法用于绝经后淋巴结阳性患者的疗效比较 - Suppr | 超能文献

Hormonal versus chemohormonal adjuvant therapy in node-positive postmenopausal patients.

作者信息

Haq A U, Haq M B

出版信息

J Clin Oncol. 1990 Nov;8(11):1922, 1925-6.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Hormonal versus chemohormonal adjuvant therapy in node-positive postmenopausal patients.激素疗法与化疗联合激素辅助疗法用于绝经后淋巴结阳性患者的疗效比较

J Clin Oncol. 1990 Nov;8(11):1922, 1925-6.

2

Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.

J Clin Oncol. 2005 Jun 20;23(18):4237-8; author reply 4238-9. doi: 10.1200/JCO.2004.01.0207.

3

Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.bcl-2蛋白的表达可预测可手术的淋巴结阳性乳腺癌辅助治疗的疗效。

Clin Cancer Res. 1995 Feb;1(2):189-98.

4

Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.与单纯使用他莫昔芬相比，表柔比星联合他莫昔芬每周给药作为可手术、淋巴结阳性老年乳腺癌患者辅助治疗的无病生存优势：法国辅助治疗研究组08试验的6年随访结果

J Clin Oncol. 2004 Dec 1;22(23):4622-30. doi: 10.1200/JCO.2004.02.145. Epub 2004 Oct 25.

5

[Adjuvant therapy also in node-negative breast cancer?].[辅助治疗是否也适用于腋窝淋巴结阴性的乳腺癌？]

Zentralbl Gynakol. 1990;112(2):57-9.

6

Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.1987 - 2000年社区对早期乳腺癌的化疗和激素治疗应用情况

J Clin Oncol. 2006 Feb 20;24(6):872-7. doi: 10.1200/JCO.2005.03.5840.

7

Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer.辅助化疗及长期服用他莫昔芬对乳腺癌淋巴结阳性患者的内分泌影响。

Cancer Res. 1987 Jan 15;47(2):624-30.

8

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.他莫昔芬辅助治疗5年后，来曲唑延长辅助治疗对绝经后早期乳腺癌女性的成本效益分析。

Am J Manag Care. 2006 Jul;12(7):374-86.

9

Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.血管内皮生长因子和胸苷磷酸化酶在接受辅助化疗或激素治疗的淋巴结阳性乳腺癌患者中的临床相关性。

Cancer J Sci Am. 1999 Mar-Apr;5(2):101-11.

10

Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.化疗内分泌与内分泌辅助治疗用于淋巴结阴性乳腺癌的比较：雌激素和孕激素受体中心评估表达的预测价值——国际乳腺癌研究组

J Clin Oncol. 2008 Mar 20;26(9):1404-10. doi: 10.1200/JCO.2007.10.6393.

引用本文的文献

1

Chemotherapy for older women with node-positive breast cancer.老年淋巴结阳性乳腺癌女性的化疗

CMAJ. 2001 Sep 4;165(5):525, 527.